Camrelizumab
Camrelizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target programmed cell death protein 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
395 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 3 | 23 | 6 | — | 5 | 35 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 5 | 22 | 7 | — | 6 | 35 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 4 | 26 | 2 | — | 1 | 29 |
| Esophageal neoplasms | D004938 | C15 | 1 | 12 | 4 | — | 4 | 20 | |
| Nasopharyngeal neoplasms | D009303 | 1 | 14 | 5 | — | — | 19 | ||
| Immunotherapy | D007167 | 3 | 11 | 1 | — | 3 | 15 | ||
| Triple negative breast neoplasms | D064726 | 4 | 12 | 3 | — | — | 15 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 11 | 1 | — | — | 12 |
| Uterine cervical neoplasms | D002583 | 1 | 10 | 1 | — | — | 12 | ||
| Lung neoplasms | D008175 | C34.90 | 1 | 5 | 3 | — | 3 | 11 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal squamous cell carcinoma | D000077277 | 2 | 15 | — | — | 1 | 17 | ||
| Neoplasms | D009369 | C80 | 7 | 9 | — | — | 1 | 15 | |
| Colorectal neoplasms | D015179 | 6 | 10 | — | — | 2 | 13 | ||
| Squamous cell carcinoma of head and neck | D000077195 | — | 12 | — | — | — | 12 | ||
| Melanoma | D008545 | 1 | 7 | — | — | — | 8 | ||
| Cholangiocarcinoma | D018281 | C22.1 | — | 7 | — | — | — | 7 | |
| Biliary tract neoplasms | D001661 | C24.9 | 1 | 6 | — | — | — | 6 | |
| Adenocarcinoma | D000230 | — | 3 | — | — | 3 | 6 | ||
| Sarcoma | D012509 | — | 6 | — | — | — | 6 | ||
| Renal cell carcinoma | D002292 | — | 4 | — | — | 2 | 6 |
Show 47 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | 1 | — | — | — | — | 1 |
| Hyperbaric oxygenation | D006931 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 1 | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | — | — | 1 | 1 | ||
| Stents | D015607 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CAMRELIZUMAB |
| INN | camrelizumab |
| Description | Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 7CU5 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297715 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 73096E137E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDCD1
PDCD1
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,742 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
73 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more